T. Rowe Price Capital Appreciation Equity ETF TCAF
43.50 USD 0.00 (+0.00%)
Nov 12, 2026, 11:28 AM EST
43.14 Day range 43.58
34.43 52-week range 43.89
- YTD
- +13.81%
- 1 year
- +11.77%
News
benzinga.com Too Many ETFs? Record 214 Fund Launches In June Raise Questions About Market Saturation The ETF industry launched a record 214 new funds in June, led by leveraged, thematic and active strategies. And they may struggle to survive.
benzinga.com Bill Ackman's $5B Pershing Square IPO Revives A Question ETFs Already Answered: Do Investors Still Need Hedge Fund Wrappers? As Pershing Square goes public, Bill Ackman's hedge fund strategy enters a space where ETFs already offer similar investment approaches.
benzinga.com Becton, Dickinson Wins FDA Clearance For Next-Gen Breast Biopsy Device, Launch Set For 2026 The FDA clears Becton Dickinson's EnCor EnCompass breast biopsy system, with a U.S. launch planned for early 2026.
benzinga.com T. Rowe Price Adds Two Active ETFs Targeting US and International Stocks, With A Fee Waiver TACU and TACN offer U.S. and international equity exposure with a 13-month fee waiver, combining active management and cost-efficient ETF structure.
benzinga.com Tesla Stock 'Could Fall 90% Tomorrow,' Fund Manager Still Won't Buy — Here's Where He's Investing Instead A fund manager who beats 99% of his peers calls Tesla stock overvalued. Here's a look at some of his preferred investments.
benzinga.com These Under-The-Radar Active ETFs Are Gaining Ground In The US Active ETFs are gaining popularity due to potential for downside protection, declining fees, and inclusion in model portfolios. Smaller funds like JGRW, JIG, and TCAF may benefit.
benzinga.com What's Going On With Revvity Stock Today? Revvity's stock rose after FDA approval of its Auto-Pure 2400 platform integrated with the T-SPOT.TB test, improving latent TB detection efficiency in labs.